Protecting America Before the Next Health Emergency

Why Congress must reauthorize PAHPA

For **20 years**, the Pandemic and All-Hazards Preparedness Act (PAHPA) has protected Americans from disease outbreaks, bioterrorism, and natural disasters.

The landmark law, which marks its 20th anniversary in December 2026, authorizes critical Department of Health and Human Services programs to prepare for and respond to public health emergencies. But key authorizations expired in 2023, leaving Congress with unfinished business.

How PAHPA Keeps Americans Safe

Develops lifesaving medical tools

Authorizes the Biomedical Advanced Research and Development Authority (BARDA) to partner with biotech companies to develop vaccines, treatments, and other countermeasures against emerging threats.

Maintains emergency medical stockpiles


Authorizes funding for the Strategic National Stockpile to purchase, maintain, and replenish essential medicines, vaccines, and medical supplies for public health emergencies.

Strengthens countermeasures against future threats

Supports Project BioShield, which helps fund medical countermeasures against biological attacks, and the Pandemic Influenza Program, which helps prepare for future flu pandemics.

Why Reauthorization Matters

Developing treatments takes years. Manufacturing capacity cannot be built overnight. Reauthorization would help sustain the programs, resources, and public-private partnerships America needs to respond quickly when a crisis strikes.



Key Priorities for PAHPA Reauthorization

- ✓ Reauthorize PAHPA's key programs — BARDA, SNS, Project BioShield, and the Pandemic Influenza Program.
- ✓ Renew the Medical Countermeasure Priority Review Voucher program, which rewards companies that develop medical countermeasures against serious threats.
- ✓ Codify reforms — like interagency planning and budget transparency — to the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE), which coordinates federal efforts to stockpile medical countermeasures.
- ✓ Support long-term industry partnerships to preserve production capacity and strengthen countermeasures against emerging threats.

The next biological threat could emerge at any time.

Congress must reauthorize PAHPA.

Bio
Biotechnology Innovation Organization